Fig. 2

In vitro pharmacologic validation in primary patient samples. Primary samples from AML patients with a FLT3-ITD (n = 4 for midostaurin + venetoclax or n = 3 for gilteritinib + venetoclax) or b FLT3-WT (n = 3 for midostaurin + venetoclax or n = 2 for gilteritinib + venetoclax) were co-cultured with HS5 stromal cells and treated at a range of doses for 96 h. MTS reagent was added to blast cells, and absorption results averaged and analyzed by HSA. c FLT3-ITD or d FLT3-WT primary patient samples were cultivated in duplicate in Methocult media with control DMSO, 100 nM venetoclax, 100 nM midostaurin, 50 nM gilteritinib, combination of midostaurin and venetoclax, or combination of gilteritinib and venetoclax for 7–10 days, and then, colonies were counted. Results reported for midostaurin + venetoclax consist of 9 individual patients with FLT3-ITD AML and 6 individual patients with FLT3-WT AML and for midostaurin + venetoclax consist of 9 individual patients with FLT3-ITD AML and 6 individual patients with FLT3-WT AML